Contact us


Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly NabĀ®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

For more information, please visit

Patient Population Investigational Product(s) Phase Status
Triple Negative Metastatic Breast Cancer nab-Paclitaxel II/III Open and Accruing